{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:34:56Z","timestamp":1793003696209,"version":"4.5.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":42,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Korea Otsuka Pharmaceutical Co., Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    To evaluate the real-world efficacy and safety of ponatinib, we conducted a multicenter, prospective post-marketing surveillance study in patients with chronic phase (CP), accelerated phase (AP), or blast phase (BP) chronic myeloid leukemia (CML) or Philadelphia chromosome\u2013positive acute lymphoblastic leukemia (Ph\u2009+\u2009ALL), who were resistant or intolerant to prior tyrosine kinase inhibitors (TKIs) or harbored the T315I mutation. A total of 148 patients were enrolled across 24 sites: 115 with CML (92 CP-CML, 12 AP-CML, 11 BP-CML) and 33 with Ph\u2009+\u2009ALL. Ponatinib was administered as third-line therapy in 70 patients (47.3%), and 127 (85.8%) initiated treatment at 45\u00a0mg once daily. Sixty-three patients (42.6%) began ponatinib due to resistance or intolerance to prior TKIs. In CP-CML, the overall major molecular response (MMR) rate was 43.2% (35\/81), with a cumulative MMR incidence of 23.9% at week 24 among patients without prior MMR. In Ph\u2009+\u2009ALL, the overall MMR and complete cytogenetic response (CCyR) rates were 82.4% (14\/17) and 75.0% (3\/4), respectively. CP-CML patients receiving ponatinib as earlier-line therapy achieved higher MR4.5 rates than those treated later (47.4% vs. 16.1%,\n                    <jats:italic>p<\/jats:italic>\n                    \u2009=\u20090.011). The most common adverse drug reactions were rash (21.6%, 32\/148), hypertension (12.2%, 18\/148), and pyrexia (10.1%, 15\/148); two vascular occlusive events occurred. Ponatinib showed favorable real-world efficacy and manageable safety in Korean patients. Early, high-dose therapy suggests a trend toward deep molecular responses, supporting its clinical benefit in real-world practice. (ClinicalTrials.gov Identifier: NCT03709017; registered October 15, 2018)\n                  <\/jats:p>","DOI":"10.1007\/s00277-026-07053-6","type":"journal-article","created":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T18:14:41Z","timestamp":1779473681000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world outcomes of ponatinib in heavily pretreated patients with chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"105","author":[{"given":"Seok","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyeoung-Joon","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"June-Won","family":"Cheong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ho-Jin","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang Kyun","family":"Sohn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Soo","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dae Young","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Won","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong-A","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sung-Eun","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Won Sik","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunsuk","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inho","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Joon","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"So Young","family":"Chong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Jung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deog-Yeon","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hawk","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Yong","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Je-Hwan","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieun","family":"Uhm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sewon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Yi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong-Wook","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"issue":"6","key":"7053_CR1","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1002\/ajh.25792","volume":"95","author":"E Jabbour","year":"2020","unstructured":"Jabbour E, Kantarjian H (2020) Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring. Am J Hematol 95(6):691\u2013709. https:\/\/doi.org\/10.1002\/ajh.25792","journal-title":"Am J Hematol"},{"issue":"2","key":"7053_CR2","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s12185-021-03156-0","volume":"114","author":"K Kidoguchi","year":"2021","unstructured":"Kidoguchi K, Ureshino H, Kizuka-Sano H et al (2021) Efficacy and safety of ponatinib for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a case series from a single institute. Int J Hematol 114(2):199\u2013204. https:\/\/doi.org\/10.1007\/s12185-021-03156-0","journal-title":"Int J Hematol"},{"issue":"3","key":"7053_CR3","first-page":"216","volume":"16","author":"M Yilmaz","year":"2018","unstructured":"Yilmaz M, Kantarjian H, Ravandi-Kashani F, Short NJ, Jabbour E (2018) Philadelphia chromosome-positive acute lymphoblastic leukemia in adults: current treatments and future perspectives. Clin Adv Hematol Oncol 16(3):216\u2013223","journal-title":"Clin Adv Hematol Oncol"},{"issue":"15","key":"7053_CR4","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2015-09-666214","volume":"127","author":"WT Parker","year":"2016","unstructured":"Parker WT, Yeung DT, Yeoman AL et al (2016) The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood 127(15):1870\u20131880. https:\/\/doi.org\/10.1182\/blood-2015-09-666214","journal-title":"Blood"},{"key":"7053_CR5","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","volume":"369","author":"JE Cortes","year":"2013","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2013) A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med 369:1783\u20131796. https:\/\/doi.org\/10.1056\/NEJMoa1306494","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"7053_CR6","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.1182\/blood-2023-179537","volume":"142","author":"I Aldoss","year":"2023","unstructured":"Aldoss I, Ribera JM, Kantarjian H et al (2023) Ponatinib versus imatinib in patients with newly diagnosed Ph\u2009+\u2009ALL: subgroup analysis of the phase 3 PhALLCON study. Blood 142(suppl 1):2871. https:\/\/doi.org\/10.1182\/blood-2023-179537","journal-title":"Blood"},{"issue":"8","key":"7053_CR7","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/jjco\/hyae061","volume":"54","author":"N Takahashi","year":"2024","unstructured":"Takahashi N, Kondo T, Ikari Y et al (2024) Real-world outcomes of ponatinib treatment in 724 patients with CML and Ph\u2009+\u2009ALL: a post-marketing surveillance study with a special interest in arterial occlusive events in Japan. Jpn J Clin Oncol 54(8):930\u2013938. https:\/\/doi.org\/10.1093\/jjco\/hyae061","journal-title":"Jpn J Clin Oncol"},{"key":"7053_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2024.107542","volume":"143","author":"DY Shin","year":"2024","unstructured":"Shin DY, Park S, Jang E, Kong JH, Won YW, Oh S et al (2024) Early dose reduction of dasatinib does not compromise clinical outcomes in patients with chronic myeloid leukemia: a comparative analysis of two prospective trials. Leuk Res 143:107542. https:\/\/doi.org\/10.1016\/j.leukres.2024.107542","journal-title":"Leuk Res"},{"issue":"6","key":"7053_CR9","doi-asserted-by":"publisher","first-page":"e521","DOI":"10.1016\/j.clml.2021.01.020","volume":"21","author":"H Shin","year":"2021","unstructured":"Shin H, Ha J-E, Zang DY, Kim S-H, Do YR, Lee WS, Kim D-W, Lee JI (2021) Appropriate starting dose of Dasatinib based on analyses of dose-limiting toxicities and molecular responses in Asian patients with chronic myeloid leukemia. Clin Lymphoma Myeloma Leuk 21(6):e521\u2013e529. https:\/\/doi.org\/10.1016\/j.clml.2021.01.020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"5","key":"7053_CR10","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/cam4.1436","volume":"7","author":"H Noh","year":"2018","unstructured":"Noh H, Jung SY, Kwak JY, Kim SH, Oh SJ, Zang DY, Lee S, Park HL, Jo DJ, Shin JS, Do YR, Kim DW, Lee JI (2018) Determination of a radotinib dosage regimen based on dose-response relationships for the treatment of newly diagnosed patients with chronic myeloid leukemia. Cancer Med 7(5):1766\u20131773. https:\/\/doi.org\/10.1002\/cam4.1436","journal-title":"Cancer Med"},{"issue":"13","key":"7053_CR11","doi-asserted-by":"publisher","first-page":"2740","DOI":"10.1002\/cncr.31357","volume":"124","author":"K Naqvi","year":"2018","unstructured":"Naqvi K, Jabbour E, Skinner J, Yilmaz M, Ferrajoli A, Bose P, Thompson P, Alvarado Y, Jain N, Takahashi K, Burger J, Estrov Z, Borthakur G, Pemmaraju N, Paul S, Cortes J, Kantarjian HM (2018) Early results of lower dose dasatinib (50\u00a0mg daily) as frontline therapy for newly diagnosed chronic-phase chronic myeloid leukemia. Cancer 124(13):2740\u20132747. https:\/\/doi.org\/10.1002\/cncr.31357","journal-title":"Cancer"},{"issue":"8","key":"7053_CR12","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.3109\/10428194.2015.1113278","volume":"57","author":"H Noh","year":"2016","unstructured":"Noh H, Park MS, Kim SH, Oh SJ, Zang DY, Park HL, Cho DJ, Kim DW, Lee JI (2016) Optimization of radotinib doses for the treatment of Asian patients with chronic myelogenous leukemia based on dose-response relationship analyses. Leuk Lymphoma 57(8):1856\u20131864. https:\/\/doi.org\/10.3109\/10428194.2015.1113278","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"7053_CR13","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","volume":"122","author":"M Baccarani","year":"2013","unstructured":"Baccarani M, Deininger MW, Rosti G et al (2013) European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood 122(6):872\u201384. https:\/\/doi.org\/10.1182\/blood-2013-05-501569","journal-title":"Blood"},{"issue":"4","key":"7053_CR14","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u201384. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"4","key":"7053_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1080\/13696998.2020.1716775","volume":"23","author":"I Kamae","year":"2020","unstructured":"Kamae I, Thwaites R, Hamada A, Fernandez JL (2020) Health technology assessment in Japan: a work in progress. J Med Econ 23(4):317\u2013322. https:\/\/doi.org\/10.1080\/13696998.2020.1716775","journal-title":"J Med Econ"},{"issue":"3","key":"7053_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/jep.70074","volume":"31","author":"SR Yu","year":"2025","unstructured":"Yu SR (2025) Improving the reimbursement process for new drugs: a case study of a two-waiver system in South Korea. J Eval Clin Pract 31(3):e70074. https:\/\/doi.org\/10.1111\/jep.70074","journal-title":"J Eval Clin Pract"},{"key":"7053_CR17","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12913-025-12207-9","volume":"25","author":"J Hong","year":"2025","unstructured":"Hong J, Bae EY, Cha S et al (2025) The value-for-money assessment and funding arrangements for high-priced drugs in an era of uncertainty: a comparative analysis of national health technology assessment agencies in South Korea, England, Australia, and Canada. BMC Health Serv Res 25:74. https:\/\/doi.org\/10.1186\/s12913-025-12207-9","journal-title":"BMC Health Serv Res"},{"issue":"21","key":"7053_CR18","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"J Cortes","year":"2021","unstructured":"Cortes J, Apperley J, Lomaia E et al (2021) Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial. Blood 138(21):2042\u20132050. https:\/\/doi.org\/10.1182\/blood.2021012082","journal-title":"Blood"},{"key":"7053_CR19","unstructured":"Takeda Ponatinib in participants with resistant chronic phase chronic myeloid leukemia (CP-CML) to characterize the efficacy and safety of a range of doses (OPTIC) (NCT02467270). ClinicalTrials.gov. 2015. Available at: https:\/\/clinicaltrials.gov\/study\/NCT02467270"},{"issue":"suppl 10","key":"7053_CR20","doi-asserted-by":"publisher","first-page":"S1558","DOI":"10.21037\/tcr.2017.09.09","volume":"6","author":"J Touma","year":"2017","unstructured":"Touma J, McLachlan A, Gross A (2017) The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology. Transl Cancer Res 6(suppl 10):S1558\u20131591. https:\/\/doi.org\/10.21037\/tcr.2017.09.09","journal-title":"Transl Cancer Res"},{"key":"7053_CR21","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1038\/aps.2010.79","volume":"31","author":"Q Li","year":"2010","unstructured":"Li Q, Chen C, Chen Z et al (2010) Imatinib plasma trough concentration and its correlation with characteristics and response in Chinese CML patients. Acta Pharmacol Sin 31:999\u20131004. https:\/\/doi.org\/10.1038\/aps.2010.79","journal-title":"Acta Pharmacol Sin"},{"key":"7053_CR22","doi-asserted-by":"publisher","first-page":"2295","DOI":"10.1111\/bjh.19819","volume":"205","author":"F Huguet","year":"2024","unstructured":"Huguet F, Guerci-Bresler A, Roth-Guepin G et al (2024) Clinical outcomes in patients in any phase of CML treated with ponatinib in France: data from the TOPASE observational study. Br J Haematol 205:2295\u20132304. https:\/\/doi.org\/10.1111\/bjh.19819","journal-title":"Br J Haematol"},{"issue":"4","key":"7053_CR23","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"JE Cortes","year":"2018","unstructured":"Cortes JE, Kim DW, Pinilla-Ibarz J et al (2018) Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood 132(4):393\u2013404. https:\/\/doi.org\/10.1182\/blood-2016-09-739086","journal-title":"Blood"},{"key":"7053_CR24","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1182\/blood.2023022403","volume":"143","author":"L Veltmaat","year":"2024","unstructured":"Veltmaat L, Cortes J (2024) Arterio-occlusive events among patients with chronic myeloid leukemia on tyrosine kinase inhibitors. Blood 143:858\u2013865. https:\/\/doi.org\/10.1182\/blood.2023022403","journal-title":"Blood"},{"key":"7053_CR25","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/s41375-024-02159-0","volume":"38","author":"E Jabbour","year":"2024","unstructured":"Jabbour E, Apperley J, Cortes J et al (2024) Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trials. Leukemia 38:475\u2013481. https:\/\/doi.org\/10.1038\/s41375-024-02159-0","journal-title":"Leukemia"},{"key":"7053_CR26","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.leukres.2017.05.008","volume":"59","author":"P Valent","year":"2017","unstructured":"Valent P, Hadzijusufovic E, Hoermann G, F\u00fcreder W, Schernthaner G\u2013H, Sperr WR, Kirchmair R, Wolf D (2017) Risk factors and mechanisms contributing to TKI\u2013induced vascular events in patients with CML. Leuk Res 59:47\u201354. https:\/\/doi.org\/10.1016\/j.leukres.2017.05.008","journal-title":"Leuk Res"},{"key":"7053_CR27","unstructured":"Takeda Pharmaceuticals America Inc. ICLUSIG (ponatinib) prescribing information (2024) Available at: https:\/\/www.oncologymedinfo.com\/productsandpipeline\/iclusig-pi"}],"updated-by":[{"DOI":"10.1007\/s00277-026-07311-7","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:00:00Z","timestamp":1792800000000}}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07053-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-026-07053-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T08:06:37Z","timestamp":1793001997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-026-07053-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,22]]},"references-count":27,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["7053"],"URL":"https:\/\/doi.org\/10.1007\/s00277-026-07053-6","relation":{},"ISSN":["1432-0584"],"issn-type":[{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,22]]},"assertion":[{"value":"22 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original version of this article was revised: This article was originally published with an omitted Figure 1B.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2026","order":9,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":10,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00277-026-07311-7","URL":"https:\/\/doi.org\/10.1007\/s00277-026-07311-7","order":12,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was approved by the Institutional Review Board at each study site, and conducted in accordance with the Declaration of Helsinki and local regulations.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dong-Wook Kim has received grants, honoraria for lectures, presentations and speaker bureaus from Bristol Meyers Squibb, Novartis, Pfizer, Il-Yang and Korea Otsuka Pharmaceutical.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients for their clinical information to be used for publication.","order":3,"name":"Ethics","label":"Consent to participate\/Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"315"}}